Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858520153Aexternal-prioritypatent/GB8520153D0/en
Priority claimed from GB868612579Aexternal-prioritypatent/GB8612579D0/en
Priority claimed from DK380986Aexternal-prioritypatent/DK169730B1/en
Application filed by Beecham Group PlcfiledCriticalBeecham Group Plc
Priority to DK199400745ApriorityCriticalpatent/DK173902B1/en
Publication of DK74594ApublicationCriticalpatent/DK74594A/en
Application grantedgrantedCritical
Publication of DK173902B1publicationCriticalpatent/DK173902B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Hydrogenated Pyridines
(AREA)
Abstract
A compound having the formula II <IMAGE> where R<3> is hydrogen, alkyl or aralkyl, R<4> is alkyl, and Ar is 4-fluorophenyl, is reduced, after which the compound having the formula I <IMAGE> which has been formed is converted into paroxetine.
DK199400745A1985-08-101994-06-22Process for preparing paroxetine or a pharmaceutically acceptable salt thereof
DK173902B1
(en)
Procedure for the preparation of 1-(3-mercaptan-(2s)-methylpropionyl)-pyrolidine-(2s)-carb<543>oxylic acid or its pharmaceutically acceptable salts.